Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31249652 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2CTBP2CYP1A2POLBALDH1A1 | |
| SCHEMBL4993803 | 0.89 | CTBP2 (0.60) | SMN1; SMN2CTBP2CYP1A2POLBALDH1A1 | |
| SCHEMBL27424890 | 0.88 | CTBP2 (0.56) | SMN1; SMN2CTBP2CYP1A2POLBALDH1A1 | |
| SCHEMBL12400239 | 0.87 | SLC7A5 (0.68) | SMN1; SMN2ALDH1A1SLC7A5 | |
| SCHEMBL4071390 | 0.85 | CTBP2 (0.64) | SMN1; SMN2CTBP2CYP1A2POLBALDH1A1 | |
| SCHEMBL511950 | 0.85 | POLB (0.56) | CTBP2CYP1A2POLBALDH1A1 | |
| SCHEMBL4993817 | 0.85 | CTBP2 (0.56) | SMN1; SMN2CTBP2CYP1A2POLBALDH1A1 | |
| SCHEMBL29640755 | 0.85 | POLB (0.56) | CTBP2CYP1A2POLBALDH1A1 | |
| SCHEMBL4634509 | 0.85 | SLC7A5 (0.55) | SMN1; SMN2CTBP2POLBALDH1A1HTT | |
| SCHEMBL6496853 | 0.85 | POLB (0.59) | SMN1; SMN2CTBP2POLBALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096421-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096417-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096424-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096418-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096420-A | A kind of catalyst and olefine polymerizing process for olefinic polymerization | 中国石油化工股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-107033006-B | Preparation method of diaryl ketone | 长沙理工大学 | 2018-12-18 | — | — | CN | claimed |
| CN-108440299-A | A method of preparing 4- nitro benzophenone class compounds | 长沙理工大学 | 2018-08-24 | — | — | CN | claimed |
| CN-107033006-A | Preparation method of diaryl ketone | 长沙理工大学 | 2017-08-11 | — | — | CN | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-0910563-A4 | — | — | 1999-04-28 | — | — | EP | disclosed |
| EP-0910563-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5869658-A | POLYMERIC ORGANIC HOST MATERIALS THAT CONTAIN OR THAT ARE COATED WITH THE NOVEL NAPHTHOPYRAN COMPOUNDS, LENSES | PPG INDUSTRIES, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998030542-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
| CN-1186806-A | Integrin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1998-07-08 | — | — | CN | disclosed |
| WO-1997001540-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | SMN1; SMN2 4305/4885CTBP2 3331/4885CYP1A2 2054/4885 |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | SMN1; SMN2 2355/4885CTBP2 2061/4885CYP1A2 1141/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | SMN1; SMN2 1733/4885CTBP2 2513/4885CYP1A2 1145/4885 |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | SMN1; SMN2 1247/4885CTBP2 2112/4885CYP1A2 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.